Der Anaesthesist
-
It is a strange contradiction that increasingly sophisticated anaesthesia machines are developed meeting all requirements for rebreathing techniques and the highest safety standards, but the usual anaesthetic management is still based on the use of fresh gas flows that preclude substantial rebreathing. The advantages of rebreathing can only be realised if low-flow anesthesia techniques are adopted. Increasing acceptance of these methods is due to the availability of comprehensive anaesthetic gas monitoring. ⋯ The use of new inhalational anaesthetics such as desflurane that require comparatively high concentrations, or even xenon, will motivate to sparing use. Increasingly stringent health and safety regulations as well as sharpened ecological awareness will prompt anaesthetists to minimise all anaesthetic gas emission according to the possibilities of available equipment. Last but not least, the demand for economical working methods will be an argument for applying low-flow anaesthesia techniques.
-
Review Comparative Study
[Sufentanil. An alternative to fentanyl/alfentanil?].
The introduction of the new opioid, sufentanil, into clinical practice should focus on the following questions: (1) What are the pharmacokinetic features of sufentanil that make it different from the well-established congeners alfentanil and fentanyl and open the way to new perspectives? and (2) Does sufentanil offer any particular advantages for specialised surgical procedures that make it the drug of first choice? Pharmacokinetics. Sufentanil is a potent analgesic with a very high receptor affinity and specificity, high lipid solubility, marked protein binding, and a shorter elimination half-life than fentanyl. Due to the high hepatic extraction ratio, metabolic degradation and elimination depend more on hepatic perfusion than on enzyme activity or renal clearance. ⋯ Epidural application of 10-50 micrograms sufentanil provides rapid and effective pain relief within 5-7 min for a period of 3-7 h. Doses of more than 50 micrograms seem to increase the risk of respiratory depression without further improvement of analgesia. Analgesia may be enhanced by combination with local anaesthetics or clonidine.(ABSTRACT TRUNCATED AT 400 WORDS)
-
Randomized Controlled Trial Comparative Study Clinical Trial
[No better vigilance after general anesthesia with propofol in colonic surgery. A comparison of three procedures for general anesthesia (propofol, halothane and midazolam/fentanyl) in combination with catheter epidural anesthesia].
Early mental and psychomotor recovery was studied in 67 patients undergoing colorectal surgery under continuous epidural anaesthesia and light general anaesthesia using propofol, halothane, and midazolam/fentanyl. The study was approved by the local ethics committee. All patients received epidural anaesthesia with 0.25% bupivacaine and were then randomly allocated to one of three groups. ⋯ It is concluded that propofol offers no advantage over halothane or midazolam/fentanyl where early postoperative recovery is concerned. Intraoperatively, all three techniques provided good anaesthesia. Propofol and midazolam/fentanyl caused less postoperative nausea and vomiting than halothane anaesthesia.
-
Clinical Trial
[The effect of substitution with AT III- and PPSB-concentrates in patients with terminal liver insufficiency].
Patients with end-stage liver disease frequently develop combined coagulopathies due to increased procoagulant and fibrinolytic turnover as well as thrombocytopenia. The onset of clinical symptoms of a haemorrhagic diathesis requires balanced substitution of coagulation factors, since fresh frozen plasma alone does not always maintain a sufficient haemostatic potential in these patients. This substitution commonly follows standard rules based on the assumption that 0.5-1 IU of a coagulation factor or inhibitor concentrate given per kg body weight will increase its endogenous activity by 1%. We set out to investigate the validity of this standard regime in patients with end-stage liver disease scheduled for orthotopic liver transplantation. ⋯ In patients with end-stage liver disease standard rules for substitution with AT III-concentrate are adequate only for patients with CLF. In patients with ALF higher AT III doses are required to achieve the expected effect on endogenous AT III activity. Procoagulant activity, as reflected by PT, can be increased by 1% when 1.6 IU/kg PPSB concentrate is given. However, this study shows the effects of coagulation concentrates only 30 min after administration. An increased volume of distribution and increased turnover may explain the poor recovery of AT III activity in the ALF group, indicating that the dose of coagulation concentrate should be estimated against the background of the patient's clinical symptoms and diagnosis.
-
A 45-year-old, healthy, well-trained man climbed within 12 hours from 300 m above sea level to a shelter at 2500 m in the Tyrolean Alps. During the following 3 days he undertook ski tours to the surrounding mountains up to 3356 m. On the 4th day he suddenly suffered from headache, coughing and very severe dyspnoea even at rest, accompanied by loss of appetite and the feeling of suffocation. ⋯ HAPE is a non-cardiogenic pulmonary edema which develops in healthy individuals usually above 3000 m. Among the predisposing factors are rapid ascent, severe physical effort, diminished hypoxic ventilatory response and abnormal fluid balance. The treatment of choice is descent to a lower altitude, administration of oxygen and of nifedipine and expiratory positive airway pressure.